Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    22-October-2000      
Issue 192 Next Update - 14:00 UTC 08:00 EST    23-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya FDA Grants Marketing Approval For Urological Cryosrugery Device

New Device Features Direct Probe Access for Targeted CryoAblation Procedure

Endocare Inc. received clearance from the FDA to market its Percutaneous Access Introducer. The device is designed for use with Endocare's Cryocare Surgical System during urological ryosurgery.

Endocare Chairman and CEO Paul Mikus commented, "This introducer device benefits the patient by enabling physicians to perform cryosurgery more quickly, with minimal invasion. It also facilitates training of physicians for this advanced procedure."

About Targeted Cryoablation

Targeted cryoablation, a procedure developed by Endocare, Inc., is the use of cryoablation (application of extreme cold to destroy tissue) in combination with ultrasound and temperature monitoring to precisely destroy cancer cells in and around the prostate gland. Liquefied argon gas, which is contained within the Cryoprobe tips, freezes and destroys the cancer and tissue that reaches -40 degrees Celsius. After approximately 10 minutes, the physician completes the first freeze cycle, then immediately administers another treatment to help ensure that all cancer cells are killed. The entire procedure lasts about one to two hours.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.